Eyal Attar

Dr. Eyal Attar has over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics.
Previously, Dr. Attar was CMO of Vor Bio, a publicly traded, clinical-stage cell and genome engineering company developing clinical therapeutics for patients with cancer. Prior to Vor, Attar served as senior vice president and CMO for Aprea Therapeutics where he led development of Aprea’s research programs, including overseeing clinical development, pharmacovigilance and regulatory filings. Before Aprea, he held multiple positions in clinical development at Agios Pharmaceuticals, where he worked on various solid tumor oncology and hematologic malignancy programs and contributed to the successful filing of multiple INDs. Dr. Attar was previously an attending hematologist/oncologist at Massachusetts General Hospital focusing on leukemias, MDS, and other hematologic malignancies affecting the bone marrow.
Dr. Eyal Attar completed fellowship training at Dana-Farber Cancer Center and residency at Brigham and Women’s Hospital. Dr. Attar received his medical degree from the University of North Carolina School of Medicine.